Dual targeting of CD44 and FAK (using anti-CD44 and the clinical grade FAK inhibitor defactinib) synergistically inhibit adhesion of the most primitive CD34high AML cells that are associated with CAM-DR and relapse. This evidence concerns the gene CD44 and acute myeloid leukemia.